Abstract

Red blood cell distribution width (RDW), which measures the range of variation of red blood cell volume, has been explored as a prognostic factor in multiple types of cancer. However, the role of RDW in mantle cell lymphoma (MCL), a rare type of non‐Hodgkin lymphoma with poor outcomes, remains to be determined. Therefore, we investigated the prognostic role of RDW in MCL. We found that 21 of 76 MCL patients (27.6%) had an abnormally elevated RDW (>15.7%). Abnormally elevated RDW was significantly associated with presence of B symptoms (P = 0.0020), elevated lactate dehydrogenase (LDH) (P = 0.0010), higher leukocyte count (P = 0.0345), higher simplified Mantle Cell International Prognostic Index (sMIPI) (P = 0.0194), and lower level of hemoglobin (Hb) (P < 0.0001). It was marginally associated with increased C‐reactive protein (P = 0.0862). RDW was significantly correlated with Hb level (r2 = 0.42) and LDH level (r2 = 0.19). 15.8% was determined as the best cutoff of RDW in predicting the survival outcome by the X‐tile software. Survival analysis revealed that high RDW (>15.8%) predicted shorter progression‐free survival (PFS) (hazards ratio [HR]: 3.14; P = 0.0005) and shorter overall survival (OS) (HR: 4.04; P < 0.0001). High RDW independently predicted both shorter PFS (P = 0.0493) and OS (P = 0.0118). RDW also improved the prognostic stratification based on sMIPI. In conclusion, our study identified RDW as a novel prognostic factor of clinical feasibility in the prognostication of MCL.

Details

Title
Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma
Author
Miao, Yi 1   VIAFID ORCID Logo  ; Xiao-Hui, Zhou 1 ; Jing-Jing, Guo 1 ; Sun, Qian 1 ; Shi, Ke 1   VIAFID ORCID Logo  ; Jia‐Zhu Wu 1 ; Hua‐Yuan Zhu 1 ; Wang, Li 1 ; Fan, Lei 1 ; Xu, Wei 1   VIAFID ORCID Logo  ; Jian‐Yong Li 1   VIAFID ORCID Logo 

 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China 
Pages
2751-2758
Section
CLINICAL CANCER RESEARCH
Publication year
2019
Publication date
Jun 2019
Publisher
John Wiley & Sons, Inc.
e-ISSN
20457634
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2242886544
Copyright
Copyright John Wiley & Sons, Inc. Jun 2019